AFM
SBBP

Anson Funds Management’s Strongbridge Biopharma plc. SBBP Stock Holding History

Anson Funds Management’s Portfolio SBBP Stock Details SBBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-92,219
Closed -$221K – 89
2016
Q4 		$221K Buy
+92,219
New +$376K 0.07% 75

Other funds holding SBBP

CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
TAF
Tredje AP-fonden Se-111 91 Stockholm, Sweden $22.1B AUM 41.68% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Anson Funds Management's SBBP Position: Q1 2017 in Review

Anson Funds Management sold out of Strongbridge Biopharma plc. (SBBP) in Q1 2017, closing a stake of 92,219 shares — an estimated $221K sold.

Anson Funds Management first reported a position in SBBP in Q4 2016 and held it in 1 quarter. The position peaked at $221K in Q4 2016. 19 funds tracked by Wall St. Rank hold SBBP as of Q1 2017.

  • Anson Funds Management reported no remaining Strongbridge Biopharma plc. position as of Q1 2017 after selling out during the quarter.
  • Anson Funds Management sold 92,219 Strongbridge Biopharma plc. shares in Q1 2017, an estimated $221K.
  • Anson Funds Management first reported a position in Strongbridge Biopharma plc. in Q4 2016 and held it in 1 quarter.
  • Anson Funds Management's Strongbridge Biopharma plc. position peaked at $221K in Q4 2016.
  • 19 funds tracked by Wall St. Rank held Strongbridge Biopharma plc. as of Q1 2017.

Based on Anson Funds Management's 13F filing for Q1 2017, filed 15 May 2017.